As a condition of publication of phase III clinical trials, medical journals should insist on the release of all raw data and a written independent clinical audit
Editorials and commentaries in some high-profile journals herald an upcoming revolution in personalised oncology.1 However, any new treatment can only be considered an advance if it:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
Responses are now closed for this article.
No relevant disclosures.